CRWD vs PFE: Which Is the Better Buy?

Side-by-side comparison of CrowdStrike Holdings, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-22.
CrowdStrike Holdings, Inc. · Technology
$449.61
+106.1% upside to fair value
Grade C High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
CRWD has more upside to fair value (+106.1%). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric CRWD PFE
Current Price $449.61 $26.91
Fair Value Estimate $926.44 $35.00
Upside to Fair Value +106.1% +30.1%
Market Cap $114.0B $153.0B
Forward P/E -619.9x 9.5x
EV / EBITDA 981.7x 13.8x
Price / Sales 23.7x 2.4x
Price / FCF 92.0x 16.8x
Revenue Growth YoY +23.3% -1.6%
Gross Margin 74.9% 70.3%
Operating Margin -5.4% 24.7%
Return on Equity -4.7% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 1.09% 5.9%
Analyst Consensus Buy Hold
Investment Thesis
CRWD — CrowdStrike Holdings, Inc.
CrowdStrike Holdings, Inc. is a leading cybersecurity company specializing in cloud-native endpoint protection and threat intelligence through its Falcon platform, which generates over 94% of its revenue from subscription services. The business quality is high due to its durable competitive moat built on cutting-edge big data security technology, strong management with a founder-led CEO who has o…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric CRWD PFE
Zone Low $694.83 $25.00
Zone High $787.47 $29.00
In Buy Zone? Yes Yes
← CRWD Research    PFE Research →    All Research